JUPITER, Fla. — Like the Greek mythological beast with a snake’s tail and two ferocious heads, a potential Parkinson’s medicine created in the lab of chemist Matthew Disney, Ph.D., is also a type of chimera bearing two heads. One seeks out a key piece of Parkinson’s-causing RNA, while the other...
research News
SAN DIEGO, Calif. – TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-1...
PARIS, France – People living with HIV need to take antiretroviral treatment for life to prevent the virus from multiplying in their body. But some people, known as “post-treatment controllers,” have been able to discontinue their treatment while maintaining an undetectable viral load for several years. Starting treatment early could...
SEATTLE, Wash. – Combined, infection, autoimmunity and cancer account for four out of every 10 deaths worldwide, and represent major global health challenges. In a just-published paper in the journal Cell Reports, Institute for Systems Biology (ISB) researchers highlight a novel discovery of how the human immune system works in...
CAMBRIDGE, Mass. – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced new data supporting novel capabilities of its CRISPR/Cas9 genome editing platform, which the Company plans to leverage for the development of...
CAMBRIDGE, Mass. – Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of preclinical data establishing proof-of-concept for non-viral genome editing of bone marrow and hematopoietic stem cells (HSCs) in mice. This represents the company’s first demonstration of systemic in vivo genome editing in tissue outside the liver using its proprietary...
NEW YORK – Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021. Ms. Rosa-Bjorkeson has more than 25 years...
Aurora, Colorado – New research led by University of Colorado School of Medicine faculty members Fan Zhang, Ph.D., and Anna Helena Jonsson, M.D., Ph.D., may lead to new targeted treatments for rheumatoid arthritis (RA), an autoimmune disease that causes joint inflammation and destruction. Published today in the journal Nature, their findings reflect the work of dozens of...
Sendai, Japan – An interim analysis of an ongoing Japanese study published in Modern Rheumatology demonstrates that mepolizumab is safe and effective in improving disease control among patients with eosinophilic granulomatosis with polyangiitis (EGPA), a form of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Remission is typically achieved and maintained in...
Boston, MA – A new international consensus report on precision medicine in diabetes prevention and care highlights the significant advancements in precision medicine in diabetes prevention, diagnosis, treatment, and prognosis while also shedding light on numerous knowledge gaps. The report, Second international consensus report on gaps and opportunities for the...